President-elect Trump has put forward biotech investor Jim O’Neill as his nominee for deputy secretary of the Health and Human Services department. This crucial position involves overseeing the daily operations of various sub-agencies within HHS, such as managing the Medicare and Medicaid programs, leading public health emergency preparedness efforts, shaping federal research initiatives, and more. O’Neill would also be responsible for developing and clearing HHS regulations, working closely with Trump’s pick for HHS secretary, Robert F. Kennedy Jr.
In a statement posted on the platform Truth Social, Trump expressed confidence in O’Neill and RFK Jr., emphasizing their shared commitment to ensuring the health and well-being of all Americans, particularly the nation’s children. O’Neill’s close relationship with billionaire Peter Thiel, his co-founding of the Thiel Fellowship, and his role as managing director of Mithril Capital Management highlight his extensive experience in the biotech investment sector. Notably, O’Neill currently serves on the board of ADvantage Therapeutics, a biotech company focused on developing therapies for Alzheimer’s disease. His advocacy for longevity medicine and libertarian views further shape his approach to healthcare.
During the previous Trump administration, O’Neill was considered for the position of Food and Drug Administration commissioner, although he ultimately lost out to a more traditional candidate. This time around, Trump is opting for more unconventional picks for key positions, with RFK Jr. leading the charge as a long-time vaccine critic and advocate for improving America’s health. The nomination of Johns Hopkins surgeon Marty Makary, a skeptic of Covid vaccine mandates, for FDA commissioner further reflects this trend.
O’Neill’s alignment with RFK Jr. on various health-related issues, including vaccine mandates and concerns about fluoride levels in drinking water, underscores their shared vision for healthcare reform. His past experience as a speechwriter and policy adviser at HHS during the George W. Bush administration provides him with valuable insights into pandemic preparedness, FDA reform, and public health initiatives.
As the role of deputy secretary at HHS requires Senate confirmation, O’Neill may face a smoother confirmation process due to his prior government experience. In the event that RFK Jr. encounters challenges in Congress, O’Neill could potentially serve as acting secretary, ensuring the continuity of leadership within the department. Overall, O’Neill’s nomination signals a shift towards more unconventional and anti-establishment figures in the Trump administration’s approach to healthcare policy.
